Last reviewed · How we verify
MIL62
MIL62 is a monoclonal antibody targeting IL-6 receptor to inhibit interleukin-6 signaling and reduce inflammatory responses.
MIL62 is a monoclonal antibody targeting IL-6 receptor to inhibit interleukin-6 signaling and reduce inflammatory responses. Used for Rheumatoid arthritis, Other IL-6-driven inflammatory conditions.
At a glance
| Generic name | MIL62 |
|---|---|
| Sponsor | Beijing Mabworks Biotech Co., Ltd. |
| Drug class | IL-6 receptor antagonist monoclonal antibody |
| Target | IL-6R (Interleukin-6 receptor) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
MIL62 binds to the IL-6 receptor, blocking the interaction between IL-6 cytokine and its receptor on immune and other cells. This inhibition suppresses downstream inflammatory signaling pathways, reducing the production of pro-inflammatory mediators and modulating immune cell activation. The mechanism is designed to address inflammatory and autoimmune conditions driven by IL-6 overexpression.
Approved indications
- Rheumatoid arthritis
- Other IL-6-driven inflammatory conditions
Common side effects
- Infection (including serious infections)
- Elevated liver enzymes
- Neutropenia
- Hyperlipidemia
Key clinical trials
- A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus (PHASE3)
- A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus (PHASE2)
- A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy (PHASE1, PHASE2)
- A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) (PHASE3)
- A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy (PHASE3)
- Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis (PHASE1, PHASE2)
- A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas (PHASE1)
- MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MIL62 CI brief — competitive landscape report
- MIL62 updates RSS · CI watch RSS
- Beijing Mabworks Biotech Co., Ltd. portfolio CI